CDK1 protein offers clues to which breast cancers will resist targeted therapy

Researchers at the Garvan Institute of Medical Research have discovered that the activity of a protein called CDK1 in breast cancers is linked to how they respond to a common therapy—an insight that could inform more personalized treatment approaches for patients.